Compass Therapeutics (NASDAQ:CMPX) Now Covered by Analysts at Guggenheim

Guggenheim initiated coverage on shares of Compass Therapeutics (NASDAQ:CMPX - Free Report) in a research report released on Monday, MarketBeat reports. The firm issued a buy rating and a $12.00 target price on the stock.

A number of other research firms also recently commented on CMPX. D. Boral Capital reissued a "buy" rating and issued a $32.00 target price on shares of Compass Therapeutics in a report on Wednesday, January 8th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Jefferies Financial Group raised their price target on Compass Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a research report on Monday, February 10th. Leerink Partnrs downgraded Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, November 15th. Finally, Piper Sandler assumed coverage on Compass Therapeutics in a research report on Wednesday, February 19th. They set an "overweight" rating and a $12.00 price objective for the company. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $11.38.

Compass Therapeutics Stock Performance

Compass Therapeutics stock traded down $0.05 during trading hours on Monday, reaching $2.92. 720,903 shares of the stock were exchanged, compared to its average volume of 1,988,024. Compass Therapeutics has a 52-week low of $0.76 and a 52-week high of $4.08. The stock has a market cap of $401.76 million, a P/E ratio of -7.89 and a beta of 1.17. The firm's 50 day moving average is $2.52 and its 200 day moving average is $1.92.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). Equities research analysts expect that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

Several large investors have recently added to or reduced their stakes in CMPX. Enavate Sciences GP LLC purchased a new stake in Compass Therapeutics in the 4th quarter valued at about $11,293,000. Tang Capital Management LLC boosted its position in shares of Compass Therapeutics by 225.4% in the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock worth $8,555,000 after acquiring an additional 4,087,005 shares during the last quarter. MPM Bioimpact LLC grew its holdings in Compass Therapeutics by 51.9% in the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock valued at $12,423,000 after purchasing an additional 2,926,002 shares during the period. SG Americas Securities LLC grew its holdings in Compass Therapeutics by 921.6% in the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company's stock valued at $573,000 after purchasing an additional 356,352 shares during the period. Finally, JPMorgan Chase & Co. increased its position in Compass Therapeutics by 512.5% during the fourth quarter. JPMorgan Chase & Co. now owns 272,328 shares of the company's stock worth $395,000 after purchasing an additional 227,864 shares during the last quarter. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.